Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Taeho Greg Rhee, Pasha A Davoudian, Gerard Sanacora, Samuel T Wilkinson
Drug discovery today December 1, 2023 DOI: 10.1016/j.drudis.2023.103818 via PubMed
Summary
AI-generated from the abstractPsychiatric disorders are the leading cause of disability globally, and interest in psychedelic substances as potential treatments has recently revived. This review examines the therapeutic potential and safety concerns of psilocybin, DMT, LSD, and MDMA, including their possible interactions with psychotherapy. It covers active and recently completed clinical trials drawn from published literature, conference abstracts, clinical trial registries, and press releases. The review suggests that these compounds may offer new avenues for treating psychiatric disorders, though safety considerations remain important.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety Depression |
| Keywords | Posttraumatic stress disorder Psychiatric disorders Psychedelics hallucinogens |
| Citations | 20 |
| Key finding | Psychedelic compounds such as psilocybin, DMT, LSD, and MDMA show potential therapeutic effects for psychiatric disorders, but safety concerns and interactions with psychotherapy require further investigation. |
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential interactive effects these compounds can have with psychotherapeutic approaches. We provide a cutting-edge review of active and recently completed clinical trials based on the published literature (from MEDLINE), published abstracts at citable conferences, clinical trials from the US Clinical Trials registry (clinicaltrials.gov) and media press releases.